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Dear Editor: 
We appreciate Dr. Suthers’ comments on our recent paper regarding risk score classification 
and interpretation of multigene tests in early breast cancer (1).  
We fully agree with Dr. Suthers’ arguments that differential risk classification of multigene 
tests alone is not equal to differential power of the individual assays to predict chemotherapy 
response. Sufficiently powered prospective randomized clinical trials are the highest level of 
evidence to demonstrate a relationship between risk score classification and the predictive 
value of treatment benefit for multigene tests in early breast cancer. Among the five 
multigene tests addressed in our paper, only the 70-gene Mammaprint (MMP) and the 21-
gene Recurrence Score (RS) assays have been validated in prospective randomized clinical 
trials (2,3). The TailorX clinical trial demonstrated the predictive power of RS for the lack of 
chemotherapy benefit in the low- and intermediate risk groups. The MINDACT trial 
demonstrated that high clinical risk/low genomic risk MMP patients had at least a 92% 
chance of being free of distant metastases at 5 years of follow-up without chemotherapy; it 
was not powered to determine chemotherapy benefit, and one cannot exclude such a benefit 
in these patients (3,6). Dr. Suthers correctly notes that TailorX included more patients from 
the clinically low risk than high risk category, and the biological link between response and 
parameters other than RS such as immunohistochemistry (IHC) and histological features has 
not been reported (2).  
IHC for hormone receptors (ER, PR), HER2 and Ki67 as well as histological features as 
tumor grade, size and nodal status provide prognostic information in all breast cancer 
patients and predictive power to determine adjuvant therapy options (e.g. endocrine and 
HER2-targeted therapies) in most but not all patients. The TailorX study set out to address a 
specific practical patient management question not answered adequately to date by any 
combination of these factors for a carefully defined group of patients with node-negative, 
ER+/HER2- breast cancer (2). The recently published comparative study in the OPTIMA trial 
addressed the agreement between risk classification based on multigene tests and 
immunohistochemistry, showing a similar discordance trend between these assays as in our 
study (1,4).  
Retrospective clinical trials/studies correlating gene expression profiling and biomarker 
profiles with patient survival are excellent tools to prove prognostic value not only for 
multigene tests but also for commonly used diagnostic assays as IHC. Dr. Suthers correctly 
cites data from the retrospective TransATAC study providing heterogeneous prognostic 
information on six measurements including multigene tests on the same tumor tissue such as 
RS, EPClin (Endopredict), ROR (Prosigna), BCI (Breast Cancer Index) and also IHC and 
CTS (Clinical Treatment Score) against observed recurrence risk (6). As previously noted in 
the OPTIMA trial and observed in our study, all these assays had been constructed and 
validated on different patient cohorts including heterogeneous clinical, nodal and 
demographic status resulting in different classification power of the individual assays even 
though the test is carried on the same tumor sample (1,4).  
With respect to Dr. Suthers’ reference to the Danish Breast Cancer Group 77B study (7), we 
point out that this level 2 evidence reporting lack of benefit for adjuvant cyclophosphamide 
monotherapy or CMF is based on 134 patients who received chemotherapy, and 31 who did 
not. The study, conducted in 1979, was agnostic to any receptor status, and premenopausal 
women received no adjuvant endocrine therapy. The Luminal A definition applied (ER and or 
PR >1%/HER2-negative with PR>20% and Ki67 <14% was very sensitive to the PR cut-point 
chosen. The authors themselves, in their extensive summary of limitations and caveats, cite 
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panels do not provide as much prognostic information”, and “do not have the same level of 
analytical reproducibility”.  
We feel that currently available multigene tests should not be used interchangeably nor 
applied in parallel on the same patient’s tissue and that incorporation of risk score 
classification in treatment decision should be done in the context of what the parent 
prospective randomized clinical or retrospective comparative trials can responsibly inform the 
user about (i.e. prognosis versus prediction in a clearly defined population with a relevant, 
contemporary treatment regimen). Retrospective comparison of multigene tests on the same 
tissue sample can be easily misinterpreted if the risk score interpretation is taken out of the 
context from how the assay was constructed and validated. 
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